Abstract: Sustained-release composite particles having improved dispersion stability and improved sustained-release properties, and exhibiting longer-term effects, a method for producing the sustained-release composite particles, a dry powder comprising the sustained-release composite particles, and wallpaper comprising the sustained-release composite particles. The sustained-release composite particles comprise core particles containing at least one type of polymer and at least one type of functional component, and micronized cellulose coating at least a part of the surface of the core particles, the core particles and the micronized cellulose being inseparable from each other.

Abstract: Methods for predicting risk of developing colorectal cancer, for treating colorectal cancer, and reducing risk of developing colorectal cancer.

Abstract: A composition which comprises a biologically active agent and a polymer that exhibits a reverse thermal gelation at a physiological temperature, in a carrier, and in which the active agent is in an undissolved form is disclosed herein. Further disclosed herein are methods utilizing the compositions for treating subjects, including non-human subjects, as well as kits for preparing and using a composition. The composition is preferably a sustained release formulation, and is particularly useful for treating animals, where single-dose treatment is desired.

Abstract: Novel iron chelating group conjugated penam derivatives described herein show antibacterial activity, and could be used as antibacterial agents or beta-lactamase inhibitors (BLIs) which are of value for application in combination with other antibacterial agents.

Abstract: Exemplary embodiments of high non-aerosol foam sanitizers are disclosed herein. An exemplary embodiment of high non-aerosol foam sanitizer includes a liquid mixture that includes an alcohol, water and a surfactant mixed with and entrapping air to form a plurality of foam bubbles. Wherein more than about 50 percent of the foam bubbles have a size of between about 50 m and about 250 ?m.

Abstract: The present invention relates to a composition, the composition including a therapeutically effective amount of at least one active agent, and a base including, an amount of colloidal silica; at least one oil; and at least one surfactant, wherein the viscosity of the composition is below 1000 mPas at a shear rate of 100 l/s and at a temperature of 20° C.

Abstract: The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

Abstract: The present invention relates to a pharmaceutical composition for use as a medicament in the prophylactic or therapeutic topical treatment of viral eye infections caused by adenovirus of subtype D or influenza A virus of subtype H7. The composition in its ready-for-use formulation comprises iota carrageenan as an active antiviral ingredient and is substantially free of a metal halide salt or contains no more than 0.5% w/v of a metal halide salt.

Abstract: Examples may include a microsphere. The microsphere may include a biodegradable polymer. Furthermore, the microsphere may include a protein mixture selected from the group consisting of a protein-polyethylene glycol conjugate, the protein-polyethylene glycol conjugate and the hydrophobic anion of the organic acid, a protein and the hydrophobic anion of the organic acid, and combinations thereof. Examples may also include a method of making the microspheres. The method may further include reacting a polyethylene glycol with a protein to form a protein-PEG conjugate. In addition, the method may include protonating an amino group on the protein-PEG conjugate with a hydrophobic organic acid to form the protein-PEG conjugate salt. Furthermore, the method may include mixing the protein-PEG conjugate salt in an organic solvent with a biodegradable polymer. The method may also include emulsifying the mixture.

Abstract: The present specification describes increasing the Brix degree, nutrient transport and density, and yields of crops through the application of photoacoustic resonance to a nutrient formulation. An activated nutrient solution is obtained by forming an unactivated nutrient solution and applying to the unactivated nutrient solution a plurality of ultra-rapid impulses of modulated laser light, from one or more laser systems, wherein said ultra-rapid impulses are defined as impulses with molecular traverse rates ranging from 100 nanoseconds to 0.01 femtoseconds. In one embodiment, an increase of at least 10% in the Brix degree of the crop, relative to an unactivated nutrient formulation, can be achieved. In addition, an increase of at least 10%, relative to an unactivated nutrient formulation, is seen with respect to nutrient density and crop yield through application of the activated nutrient solution.

Abstract: A method for the treatment or prophylaxis of non-inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome or other non-specific bowel disorder is disclosed comprising administering to a patient in need of such treatment or prophylaxis an effective amount of balsalazide, or a 4-ASA or 5-ASA compound modified to include a 4-ABA side chain, or a salt or a derivative thereof, or a composition comprising balsalazide the modified compound, or a salt or a derivative thereof together with a suitable carrier. Use of balsalazide, a 4-ASA or 5-ASA compound modified to include a 4-ABA side chain, or a salt or derivative thereof, for the manufacture of a medicament for the treatment or prophylaxis of non-inflammatory bowel diseases, diarrhea-predominant Irritable Bowel Syndrome or other non-specific bowel disorder is also disclosed.

Abstract: The proposed compositions and methods for preparation thereof relate to pharmacology, medicine, veterinary science and pharmaceutical industry. The compositions can be used for preparing infusion solutions of antimicrobial (antibacterial and antifungal) preparations increasing therapeutic efficiency thereof. The compositions include nanostructured colloidal silica and are efficient when treating overwhelming sepsis of tested animals, provoked by Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Candida albicans. The pharmaceutical compositions have a proven and significant clinically important potentiating impact on therapeutic efficiency of the infusion solutions, when treating inflammatory diseases, in comparison with traditional solvents.

Abstract: The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram-positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens.

Abstract: Techniques for treating one or more diseases of altered IgE regulation in a patient are provided. For example, a technique for treating one or more diseases of altered IgE regulation in a patient includes the step of administering a therapeutically effective amount of one or more sophorolipids to the patient in a manner which decreases IgE production in the patient. Further, the technique for treating one or more diseases of altered IgE regulation may include administering a therapeutically effective amount of one or more sophorolipids intravenously, intramuscularly, as an inhalant, subcutaneously, topically and/or systemically.

Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.

Abstract: A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition.

Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents; and the amount of viscosity modifying agents can optionally be reduced by at least an amount by weight that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%; wherein the tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline

Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.

Abstract: The present invention relates to a composition for bath additives characterized in that the composition is obtained by a process comprising: subjecting herbal materials to liquid phase fermentation with Bacillus subtilis to obtain a culture, the herbal materials comprising 10% to 25% by weight of Zizania latifolia, 10% to 20% by weight of Artemisia capillaries, 5% to 15% by weight of Houttuynia cordata, 1% to 20% by weight of Saururus chinensis, 1% to 15% by weight of Leonurus sibiricus, 1% to 15% by weight of Angelica gigas, 1% to 15% by weight of Coix lachryma-jobi, 1% to 10% by weight of Plantago asiatica and 1% to 10% by weight of Rhododendron brachycarpum, based on a total dry weight of the herb materials; separating sludge from the resulting culture; and drying, sterilizing and pulverizing the sludge.

Abstract: [Objects] An object of the present invention is to provide an orally administrable agent for medical use for animals for preventing or treating coccidiosis which is highly safe with no side effects, an agent for a food or a drink for use in the preservation of health, a feed additive, and a feed comprising the same. Another object of the present invention is to provide a method for rearing animals (particularly, livestock and poultry) using the same and a method for controlling coccidiosis using the same. [Means for Resolution] By using a fermentation product of a lactic acid bacterium and/or a whey fermentation product of a propionic acid bacterium as an active ingredient, an agent for preventing or treating coccidiosis, an agent for use in the preservation of health, and a feed additive can be provided.

Abstract: The present invention relates to the antagonistic bacteria that are used to prevent and eliminate tobacco bacterial wilt and their microbial organic fertilizer, which belong to the technology for agricultural intensive production. The present invention separates two antagonistic bacteria (Brevibacillus brevis NJL-25 and Bacillus cereus NJL-14) that have remarkable antagonistic action against the pathogens of tobacco bacterial wilt. Microbial organic fertilizer is produced from these antagonistic bacteria and organic compost. Wherein, the content of each of NJL-25 and NJL-14 is above 1×1010 cfu/g, the content of total nitrogen is 4˜5% (above 90% of the nitrogen is organic nitrogen), the content of total nitrogen-phosphorus-kalium nutrient is 6˜10% and the content of organic matter is 30˜35%. As indicated by experiments, after the microbial organic fertilizer is applied into soil, it will enable rapid multiplication of the antagonistic bacteria into a dominant microflora in the soil and achieve more than 97.

Abstract: The present invention relates to a composition for bath additives characterized in that the composition is obtained by a process comprising subjecting herbal materials comprising 10˜25% by weight of Zizania latifolia, 10˜20% by weight of Artemisia capillaries, 5˜15% by weight of Houttuynia cordata, 1˜20% by weight of Saururus chinensis, 1˜15% by weight of Leonurus sibiricus, 1˜15% by weight of Angelica gigas, 1˜15% by weight of Coix lachryma-jobi, 1˜10% by weight of Plantago asiatica and 1˜10% by weight of Rhododendron brachycarpum, based on the total dry weight of the above herb materials, to liquid phase fermentation with Bacillus subtilis which is anaerobic, to obtain a culture, separating sludge from the resulting culture, drying, sterilizing and pulverizing the culture to give a pulverized sludge, and a process for preparing the same.

Abstract: The invention relates to medicine and the chemical and pharmaceutical industry, in particular to antibiotic preparative forms. The inventive antimicrobial composition contains antibiotic selected from a group of lincosamides, broad-spectrum penicillins, cephalosporins, macrolides, tetracyclines, and lactulose at the active component ratio of 1:1-1:100. The mean particle size of lactulose ranges from 100 nm to 200 ?m. Said composition is embeddable in a solid state and in the form of a syrup or a suspension. When applicable, pharmaceutically acceptable excipients are added into the composition in such a way that it takes a form acceptable for peroral administration.

Abstract: The invention relates to superfine microparticles and nanoparticles and a process for their gentle preparation with exclusion of water or minimization of water and/or exclusion of plasticizers and/or reduced temperature load, in which a matrix material is subjected to a high-pressure homogenization process in an anhydrous or water-poor medium and/or at low temperatures, preferably room temperature (20° C.) and in particular below the freezing point of water, which leads to a gentle particle reduction with minimization of the impairment of the chemical stability of the homogenized material.

Abstract: Disclosed is a method of diagnosing autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis an autoimmune disease. Also disclosed is a method of treating these autoimmune diseases, which involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of antimicrobial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. Also disclosed is a kit for the diagnosis or treatment of autoimmune diseases.

Abstract: The present invention relates to the antagonistic bacteria that are used to prevent and eliminate tobacco bacterial wilt and their microbial organic fertilizer, which belong to the technology for agricultural intensive production. The present invention separates two antagonistic bacteria (Brevibacillus brevis NJL-25 and Bacillus cereus NJL-14) that have remarkable antagonistic action against the pathogens of tobacco bacterial wilt. Microbial organic fertilizer is produced from these antagonistic bacteria and organic compost. Wherein, the content of each of NJL-25 and NJL-14 is above 1×1010 cfu/g, the content of total nitrogen is 4˜5% (above 90% of the nitrogen is organic nitrogen), the content of total nitrogen-phosphorus-kalium nutrient is 6˜10% and the content of organic matter is 30˜35%. As indicated by experiments, after the microbial organic fertilizer is applied into soil, it will enable rapid multiplication of the antagonistic bacteria into a dominant microflora in the soil and achieve more than 97.

Abstract: [Objects] An object of the present invention is to provide an orally administrable agent for medical use for animals for preventing or treating coccidiosis which is highly safe with no side effects, an agent for a food or a drink for use in the preservation of health, a feed additive, and a feed comprising the same. Another object of the present invention is to provide a method for rearing animals (particularly, livestock and poultry) using the same and a method for controlling coccidiosis using the same. [Means for Resolution] By using a fermentation product of a lactic acid bacterium and/or a whey fermentation product of a propionic acid bacterium as an active ingredient, an agent for preventing or treating coccidiosis, an agent for use in the preservation of health, and a feed additive can be provided.

Abstract: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds.

Abstract: The present invention relates to a formulation useful to control Listeria monocytogenes that comprises three new lactic acid bacteria, namely Carnobacterium maltaromaticum ATCC® PTA-9380, C. maltaromaticum ATCC® PTA-9381 and Enterococcus mundtii ATCC® PTA-9382 together with the bacteriocin nisin. This formulation is obtained from Inactivated Fermentates (IF) of these strains plus nisin and is designed to be used in the food industry. This formulation is used as an agent with tested antagonistic and bactericidal action against the pathogen Listeria monocytogenes, the microorganism that causes listeriosis, a food-borne disease, in humans. Based on this formulation, 2 surface sanitizing products can be obtained, a liquid and a solid. Both surface sanitizers can be applied to sanitize equipments, devices, working surfaces, gutters and drainages, especially in the food industry.

Abstract: The present invention relates to antibiotic synergism of pharmaceutical compositions comprising a defensin and a beta-lactam antibiotic.

Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

Abstract: The present invention provides a composition which includes a sclareol or a derivative thereof, wherein the sclareol or a derivative thereof is bound by a glycoprotein matrix. The composition of the invention provides improved potency, stability and bioactivity characteristics of sclareol, or its derivatives.

Abstract: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds.

Abstract: The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes minimal growth inhibition of cells. Such combination therapy thus allows one to use lower doses of cytotoxic agents to avoid or reduce their respective toxicity to patients without compromising their growth inhibitory effects. Thus, these combinations can be used for the treatment of an animal, preferably a mammal, that has a cell proliferative disorder, whether the cells have wild-type Rb or are Rb deficient or Rb negative. One such method, directed to treating cell proliferative disorders includes the step of administering a therapeutic effective amount of a cytotoxic agent followed by administering a therapeutic effective amount of a heat shock protein 90 inhibitor.

Abstract: Screening procedures are disclosed for identifying compounds useful for inhibiting infection or pathogenicity. Methods are also disclosed for identifying pathogenic virulence factors.

Abstract: The anti-itch solution is a solution of hydrogen peroxide, sodium bicarbonate and apple cider vinegar applied to feet to prevent a common fungal infection of feet known as “athlete's foot”.

Abstract: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO.

Abstract: The present invention provides a composition comprising an untreated or treated culture of a mixed microorganism and a functional food comprising said composition. A composition comprising an untreated or treated culture of a mixed microorganism comprising at least three lactic acid bacteria selected from the group consisting of Lactobacillus delbrueckii, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus rhamnosus, Lactococcus lactis and Streptococcus thermophilus, mixed with Saccharomyces cerevisiae, and a functional food comprising said composition.

Abstract: This invention relates to pharmaceutical formulations comprising amoxycillin and a salt clavulanic acid in a ratio of 14:1.

Abstract: Cosmetic compositions intended for topical application to the skin for lightening and/or brightening the skin are provided. The subject compositions are characterized by the presence of leukocyte extract in combination with one or more secondary skin whitening or brightening agents. A preferred group of such agents includes bearberry, arbutin, rutin, ascorbyl glucoside, ascorbyl magnesium phosphate, hydroquinone, kojic acid or combinations thereof. Another group of preferred agents includes extracts of mulberry, lemon, orange, licorice, cucumber, cinnamon, cherry (fermentate), rosemary and/or derivatives thereof. It has been found that the combination of leukocyte extract with such agents possesses enhanced efficacy over similar preparations that do not contain leukocyte extract.

Abstract: Disclosed are a multipurpose, high-functional, alkaline solution composition, preparation therefor and use thereof as a nonspecific immunostimulator. The composition comprises 1-25 parts by weight of borax (Na2B4O7.10H2O), 10−5-10−4 parts by weight of sodium thiosulfate (Na2S2O3.5H2O), 30-150 parts by weight of potassium carbonate, 30-200 parts by weight of refined sugar (C12H22O11), and 100-200 parts by weight of water, based on 100 parts by weight of sodium metasilicate (Na2SiO3.5H2O). In addition to bringing about an improvement in disease resistance, weight gain rate, crop yield, crop quality, harvest time, the composition shows nonspecific immunostimulating activities, including antibody production and immune enhancement, by activating immune cells, thereby maximizing vaccination effects on malignant viral diseases.

Abstract: This invention provides methods and compositions for preventing and treating Clostridium difficile-associated disease in a subject, wherein the subject is either a human or non-human animal. The method comprises administering to the subject an effective amount of a non-toxigenic strain of C. difficile or a combination of strains. A suitable non-toxigenic strain is selected from the M, T, C, P, S and AP group as defined by restriction endonuclease analysis. Also provided are pharmaceutical compositions and unit dosage forms comprising a single strain or a combination of strains selected from a non-toxigenic C. difficile group and a method for selecting non-toxigenic C. difficile strains.

Abstract: A method of dispersing, in water vapor, an anti-infective therapeutic composition (10) into the air in a room (36), in order to treat or prevent transmission of upper respiratory infections, includes: adding to a reservoir of liquid water in a vaporizer (34), a therapeutic composition (10) containing one or more antibiotics (14), alcohol (16), an analgesic (18) and an expectorant (20); and vaporizing the therapeutic composition (10) into the air along with the water in the vaporizer reservoir for inhalation by persons in the room.

Abstract: A liquid aqueous pharmaceutical suspension formulation containing as amoxycillin trihydrate, potassium clavulanate and microcrystalline cellulose filler is provided.

Abstract: A pharmaceutical formulation comprises, in combination with a penem of formula (I): in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula:  wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration; and a pharmaceutically acceptable carrier; a &bgr;-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.

Abstract: Skin preparations for external use and cosmetics which contain a fermented soybean extract prepared by extracting with an organic solvent a fermentation product obtained by treating a soybean extract with one or more microorganisms selected from bifidobacteria. These preparations are excellent in the effects of relieving wrinkles and ameliorating rough skin.

Abstract: Disclosed are a multipurpose, high-functional, alkaline solution composition, preparation therefor and use thereof as a nonspecific immunostimulator. The composition comprises 1-25 parts by weight of borax (Na2B4O7.10H2O), 10−5-10−4 parts by weight of sodium thiosulfate (Na2S2O3.5H2O), 30-150 parts by weight of potassium carbonate, 30-200 parts by weight of refined sugar (C12H22O11), and 100-200 parts by weight of water, based on 100 parts by weight of sodium metasilicate (Na2SiO3.5H2O). In addition to bringing about an improvement in disease resistance, weight gain rate, crop yield, crop quality, harvest time, the composition shows nonspecific immunostimulating activities, including antibody production and immune enhancement, by activating immune cells, thereby maximizing vaccination effects on malignant viral diseases.

Abstract: Compound of formula I: wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting &bgr;-lactamase enzymes, for enhancing the activity of &bgr;-lactam antibiotics, and for treating &bgr;-lactam resistant bacterial infections in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula I, and novel intermediates useful for the synthesis of compounds of formula I.

Abstract: An anthelmintic composition including an Antibiotic S541 compound or a chemical derivative thereof, together with an insoluble anthelmintic compound. The composition is stabilized by between about 0.15% and about 5.0% of an antioxidant by weight of the total composition.

Abstract: The invention provides an antimicrobial agent capable of producing an excellent effect in the prevention or treatment of bacteria of two or more genera selected from among Streptococcus, Moraxella, Haemophilus, Klebsiella and the like. The agent comprises a penicillin antibiotic, in particular amoxicillin, and a cephem antibiotic, in particular cefixime or cefdinir. The antimicrobial agent of the invention is administered in the form of a mixed preparation containing both or in the form of individual preparations respectively containing them for combined administration.